Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 2/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27808604 | 1.00 | FDPS (0.40) | FDPSPTPN1LAP3S1PR2S1PR1 | |
| SCHEMBL6053306 | 0.90 | PTPN1 (0.38) | FDPSPTPN1LAP3TYMS | |
| Alcohol SCHEMBL13737870 | 0.82 | FDPS (0.63) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL28342576 | 0.81 | LPAR3 (0.50) | FDPSS1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL29007224 | 0.81 | LPAR3 (0.50) | FDPSS1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL28345240 | 0.81 | LPAR3 (0.50) | FDPSS1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL601976 | 0.79 | — | — | |
| SCHEMBL2251269 | 0.79 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL1259333 | 0.79 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL629521 | 0.79 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511758-A1 | METHODS FOR SEPARATING OLIGONUCLEOTIDES | Kwiatkowski, Marek (SE) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003066651-A1 | METHODS FOR SEPARATING OLIGONUCLEOTIDES | KWIATKOWSKI MAREK (SE) | 2003-08-14 | — | — | WO | disclosed |
| US-20030153741-A1 | Methods for separating oligonucleotides | QUIATECH AB (SE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153741-A1 | Methods for separating oligonucleotides | DCLRE1B, RNGTT, NUDT21 | FDPS 2892/4885PTPN1 2515/4885LAP3 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.